Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock
Key facts
- Who runs it
- Rachael Cusack
- Where
- Ireland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 100 people enrolled
- Started
- 1 Sept 2021
- Ended
- 1 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 20% Albumin
- Crystalloid
- Record updated
- 26 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Sepsis; suspected source of infection, tachycardia, tachypneic, hyperlactatemia, hypotensive requiring vasopressors, febrile >38.5degrees Celsius
- Fluid responsive; pulse pressure variability >10% or passive leg raise positive
Who cannot take part
- Heart Failure, cardiogenic shock, recent MI
- Receiving regular albumin 20%
- Fluid overloaded; pulmonary oedema, significant peripheral oedema
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The sublingual microcirculation is impaired in sepsis and septic shock. Sidestream dark field imaging technology has been developed into a clinical tool to help the clinician assess the microcirculation at the bedside. The ideal resuscitation fluid has not been identified. The investigators aim to use this new bedside technology to establish the microcirculation properties of two popular resuscitation fluids.
The 2 groups in the trial
- Interventional 20% AlbuminTreatment being tested
Septic patients requiring a fluid bolus randomised to receive 100ml 20% albumin as boluses until they are stable or no longer require fluid resuscitation.
Treatment: 20% Albumin
- Control CrystalloidExisting treatment, for comparison
Septic patients requiring a fluid bolus randomised to receive 250ml boluses of crystalloid fluid until they no longer require fluid resuscitation.
Treatment: Crystalloid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of Fluid Resuscitation with 20% Albumin Versus Crystalloid on the Microcirculation of Patients with Sepsis
- Publications
- Mid-Regional Pro-Adrenomedullin as a Translational Biomarker of Microcirculatory Dysfunction in Sepsis: A Prospective Observational Study.Medical sciences (Basel, Switzerland), 2026
- Albumin Enhances Microvascular Reactivity in Sepsis: Insights from Near-Infrared Spectroscopy and Vascular Occlusion Testing.Journal of clinical medicine, 2025
- Microcirculation properties of 20 % albumin in sepsis; a randomised controlled trial.Journal of critical care, 2025
- Record updated
- 26 October 2024